Hymecromone clinical trial is cautiously positive

Robyn Kalda
Jul 7, 2025
1 min read

A very small (16 patients) phase 2a clinical trial for pulmonary hypertension associated with interstitial lung disease (PH-ILD) looked at whether hymecromone, a drug that might help blood vessels, had any promising effects.

Overall, the results weren't statistically significant, but half the patients treated with hymecromone improved their six-minute walk distance by 66m and had improved quality of life. Researchers concluded that a larger trial is warranted.

Read the Thorax article

Recent Posts

Smoking delays PAH diagnosis, but not CTEPH

Researchers looked at whether cigarette smoking affected the diagnosis and disease progression of patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension

Environmental triggers may contribute to heritable PAH

This study tried to identify new environmental triggers or genetic causes in heritable pulmonary arterial hypertension. They found several potential genes for further exploration, but they also found

Time to diagnosis matters for patients with PAH

This study identified factors associated with a delayed diagnosis of PAH and found that earlier diagnosis (<6 months) and treatment initiation were associated with significantly improved survival. Mor

Comments